Supernus Pharmaceuticals 表示,合并后的实体预计将立即受益于规模效应。与此同时,该公司还预期每年可实现高达1.25亿美元的成本协同效应。
Supernus Pharmaceuticals 表示,合并后的实体预计将立即受益于规模效应。与此同时,该公司还预期每年可实现高达1.25亿美元的成本协同效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.